Skip to main content
SpringerLink
Log in

Liver injury during pembrolizumab therapy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Tsung I, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Alimentary Pharmacology and Therapeutics : 15 Jul 2019. Available from: URL: http://doi.org/10.1111/apt.15413

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liver injury during pembrolizumab therapy. Reactions Weekly 1763, 9 (2019). https://doi.org/10.1007/s40278-019-65101-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-65101-z

Search

Navigation